diabetic

Rosiglitazone (BRL49653) is a PPARγ agonist, TRPC5 activator, and TRPM3 inhibitor with oral activity. Rosiglitazone is also a hypoglycemic agent and a thiazolidinedione insulin sensitizer.

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Gatifloxacin hydrochloride (AM-1155 hydrochloride) is a fourth-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.

Spironolactone (SC9420) is an Aldosterone Antagonist. The mechanism of action of spironolactone is as an Aldosterone Antagonist.

Rosiglitazone hydrochloride (BRL-49653 HCl) is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells.

PF 05089771 is a Selective inhibitor of Nav1.7 (IC50 = 11 nM) that interacts with the voltage-sensor domain of domain IV. It shows a slow onset of the block that is depolarization and concentration-dependent.

Cassiaside C (Toralactone 9-O-β-D-gentiobioside), a naphthopyrone extracted from Cassia tora seeds, demonstrates in vitro inhibitory activity against the formation of advanced glycation end products (AGE).

Emodin 6-O-β-D-glucoside (Glucoemodin) can protect barrier integrity and inhibit HMGB1-mediated inflammatory responses, which suggests a potential use as a therapy for sepsis or septic shock. Emodin 6-O-beta-D-glucoside has anti-inflammatory activities and also may have significant therapeutic benefits against diabetic complications and atherosclerosis.

Compound 19, also known as Antidiabetic agent 6, is an antidiabetic compound. It stimulates the translocation of GLUT4 by activating the PI3K AKT-dependent signaling pathway. Furthermore, this compound reduces blood glucose levels in diabetic rats induced by streptozotocin.

Compound 56 (Antidiabetic agent 2) is a glucose-uptake promoter that inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase, with IC50 values of 0.036, 0.042, 0.241, and 0.185 μM, respectively. This agent effectively decreases blood glucose levels [1].

Antidiabetic agent 7 (Compound 5m) functions as a potent hyperglycemia inhibitor. It effectively stimulates GLUT4 translocation in skeletal muscle cells by activating the AMPK-dependent pathway. Additionally, this compound is capable of reducing blood glucose levels and exhibits favorable pharmacokinetic properties. Antidiabetic agent 7 is suitable for research related to antihyperglycemic treatments.

Compound S1 (antidiabetic agent 5) is an antidiabetic agent that effectively inhibits the enzymes α-glucosidase and α-amylase, demonstrating IC50 values of 3.91 µM and 8.89 µM, respectively. It reduces sugar levels and holds potential for type-II diabetes research [1].

Insulin (human) is a peptide hormone that promotes glycogen synthesis and regulates glucose levels in the blood. Insulin (human) has hypoglycemic activity and is used clinically to treat hyperglycemia in diabetic patients.

Dirlotapide (CP742033) is an intestinal selective microsomal triglyceride transfer protein (MTP) inhibitor. It reduces body weight in diabetic dogs.Dirlotapide reduces food intake in a dose-dependent manner, possibly by increasing the release of peptide YY into the circulation.

Kamuvudine-8 (K8) is a zidovudine (AZT) derivative that can be used to study diabetic macular edema.

PPA-904, a specific phenothiazine photosensitizer, is used in photodynamic therapy (PDT).

P32 98 hemifumarate is a dipeptidyl peptidase IV (DPP4) inhibitor with hypoglycemic properties that improves insulin sensitivity and β-cell responsiveness in the Zucker diabetic rat model, and may be useful in studies of type 2 diabetes and colitis.

α-NETA is a potent choline acetyltransferase (ChA) inhibitor and an ALDH1A1 and chemokine-like receptor 1 (CMKLR1) antagonist.Anti-cancer activity,Cholinesterase and acetylcholinesterase (AChE) inhibition,Dose-dependent reduction of body weight and fasting blood glucose levels in STZ-induced diabetic mice,Significantly reduced expression of renal injury markers,May be CEP-9722 can be used for the study of diabetic nephropathy.

Raxofelast (IRFI-016) is a hydrophilic, non-systemic, vitamin-like antioxidant that reduces ischemia-reperfusion injury in testis. Raxofelast is a good candidate compound for stopping oxidative stress after acute testicular torsion. Raxofelast has the potential to treat diabetic complications and atherosclerosis.

16α-Bromoepiandrosterone (BEA) is a water-soluble synthetic sterol related to DHEA and is used in studies of type II diabetes and non-diabetic tuberculosis infections.

Ranirestat (AS-3201) is an orally active and potent aldose reductase (AR) inhibitor with neuroprotective properties that ameliorates peripheral nerve dysfunction in rats with advanced diabetic polyneuropathy.Ranirestat inhibits the inflammatory response of high glucose-exposed endothelial cells and may be useful for the study of diabetic sensory-motor polyneuropathy.

Coleneuramide (MCC-257) enhances the effect of nerve growth factor (NGF) on cell survival and can be used to study diabetic polyneuropathy.

Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.

Apararenone (MT-3995) is a mineralocorticoid receptor antagonist indicated for the treatment of non-alcoholic steatohepatitis and diabetic nephropathy.